The Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has issued a positive opinion for three new…
Category: Oral Medication
AstraZeneca and Bristol-Myers Squibb Company resubmitted a New Drug Application (NDA) to the U.S. FDA for the investigational drug dapagliflozin for the treatment of adults with type 2 diabetes. The FDA assigned a new Prescription Drug User Fee Act (PDUFA) goal date of Jan. 11, 2014.
Results of the Novartis-sponsored INTERVAL study have demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes treated with Novartis drug, Galvus (vildagliptin).
“The bottom line with this drug is that it controlled blood sugar levels without causing weight gain and caused almost no hypoglycemia. This drug could be the backbone of new treatments for type 2 diabetes.”
The FDA has approved Janssen Pharmaceutical's new type 2 diabetes treatment, Invokana (canagliflozin). Invokana is the first in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors to be approved in the United States.
Takeda Pharmaceutical has received FDA approval for three new treatments for type 2 diabetes - NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl).
New research from the University of Pennsylvania has discovered that the most popular type 2 diabetes medication, metformin, works differently than previously thought. Metformin was known to lower blood glucose levels by decreasing the amount of glucose produced by the liver, but how the drug did this was not known.
The European Commission has approved Bristol-Myers Squibb and AstraZeneca's new type 2 diabetes therapy, Forxiga (dapagliflozin), for use in the European Union (EU).
Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body
The European Commission has given Marketing Authorization to Jentadueto (linagliptin/metformin hydrochloride) tablets,Boehringer Ingelheim and Eli Lilly's medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta tablets, marketed under the trade name Trajenta in Europe) and metformin in a single tablet taken twice daily.
Eli Lilly and Boehringer Ingelheim presented new data from a phase 2b open-label extension study, showing empagliflozin (BI 10773), alone or as an add-on to metformin, reduced hemoglobin A1c (HbA1c or A1c) levels, fasting plasma glucose (FPG) levels and body weight when given to adults with type 2 diabetes for up to 90 weeks...